Company news

Nippon Shinyaku Co., Ltd. news in 2025

Nippon Shinyaku Co., Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Nippon Shinyaku: ELZONRIS® I.V. Injection Receives Marketing Approval for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan

December 22, 2025

Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress

October 14, 2025

Orphan Drug Designation granted to Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

September 30, 2025

FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy

September 19, 2025

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

September 9, 2025

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases

July 1, 2025

Decks in 2025